MD1003-AMN MD1003 in Adrenomyeloneuropathy

Summary

The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day over placebo in the clinical improvement (walking tests) of patients with adrenomyeloneuropathy

Timeline

Start

2014-10

Primary completion

2016-06

Completion

2017-06

Drugs

Indications